ScripGalapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w
ScripJohnson & Johnson is discontinuing the Phase III VENTURA development program of its kappa opioid receptor (KOR) antagonist, aticaprant, as an adjunctive treatment for major depressive disorder (MD
ScripA bad case of post-holiday letdown set in for Neumora Therapeutics and its shareholders on 2 January as the brain disease-focused firm announced the failure of its kappa opioid receptor (KOR) antagoni
In VivoDROP DOWN LINKS TO STUDIES: Sanofi’s GEMINI 1 & 2 And HERCULES Trials In Multiple Sclerosis Sanofi ended 2023 with a disappointment for its cancer therapy, tusamitamab ravtansine, but in 2024 eyes w